Tüdőrák: vizsgálatok itt: Lengyelország
113 of 116 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Bialystok, Bydgoszcz, Cracow, Koszalin, Lublin, Poznan, Przemyśl, Warsaw
- Életkor
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - 3. fázisTaking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Gdansk, Kielce, Olsztyn, Poznan, Przemyśl, Warszawa, Wroclaw
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - 3. fázisTaking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Bydgoszcz, Gorlice, Katowice, Krakow, Lublin, Poznan, Prabuty, Wroclaw
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - 2. fázisNot yet taking people in LengyelországA Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
- Where
- Lodz, Przemyśl, Warsaw
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07941609 - 3. fázisNot yet taking people in LengyelországA Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
- Where
- Cracow, Warsaw
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 - 3. fázisLeállítvaLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Poznan
- Életkor
- 18 év and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - 2/3. fázisTaking peopleA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Bialystok, Cracow
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00 - 3. fázisTaking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Cracow, Katowice, Olsztyn, Przemyśl, Warsaw
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - 3. fázisTaking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Checiny, Lodz, Olsztyn, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - 2. fázisNot yet taking people in LengyelországA trial to learn how well Dato-DXd works and how safe it is with other anticancer drugs in adults with TROP2 NMR-positive non-small cell lung cancer
- Where
- Checiny, Lodz, Łódź, Przemyśl, Sosnowiec
- Életkor
- 18 év and over
- People
- 146 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524836-21-00 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Bydgoszcz, Cracow, Koszalin, Warsaw
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 3. fázisTaking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Bialystok, Cracow, Gdynia, Gliwice, Lodz, Lublin, Peremyshl, Poznan, Walbrzych, Warsaw, Wilkowice
- Életkor
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - 2. fázisTaking peopleSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Where
- Gdansk, Koszalin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 144 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00 - 2/3. fázisTaking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Bydgoszcz, Jelenia Góra, Poznan, Prabuty, Warsaw, Wieliszew
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - 1/2. fázisTaking peopleA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Where
- Cracow, Gdansk, Poznan, Tomaszow Mazowiecki
- Életkor
- 18 év and over
- People
- 880 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07111520 · EU 2024-519344-32-00 - 1/2. fázisBefejeződöttFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Gdansk, Lodz
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00 - 3. fázisTaking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Cracow, Gorlice, Lublin, Olsztyn, Peremyshl, Warsaw
- Életkor
- 18 év and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - 3. fázisTaking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- Bydgoszcz, Gdansk, Konin, Lodz, Lublin, Poznan
- Életkor
- 18 év and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - 3. fázisTaking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Gdansk, Gliwice, Lodz, Lublin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - 2/3. fázisNot yet taking people in LengyelországStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Bydgoszcz, Lublin, Poznan
- Életkor
- 18 év and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - 3. fázisTaking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Gliwice, Olsztyn, Przemyśl
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - 2. fázisTaking peopleA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Where
- Gdansk, Koszalin, Poznan, Przemyśl, Warsaw
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07221474 · EU 2025-520902-37-00 - 3. fázisTaking peopleA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Where
- Cracow, Katowice, Olsztyn, Przemyśl, Warsaw
- Életkor
- 18 év and over
- People
- 310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00 - 3. fázisNot yet taking people in LengyelországBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Where
- Bialystok, Gdynia, Katowice, Lodz, Prabuty
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT07625644 - 1/2. fázisNot yet taking people in LengyelországDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Wroclaw
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00